If radiation therapy brings the PSA level back to undetectable after cancer comes back, the patient is much more likely to live longer—even if the PSA was already high when treatment started.
Scientific Claim
In men with prostate cancer recurrence after radical prostatectomy, achieving an undetectable PSA nadir after salvage radiotherapy is associated with significantly improved long-term survival, regardless of the PSA level at which treatment was initiated.
Original Statement
“Multivariate analyses showed that nadir PSA after SRT was more highly significant for the prognosis than PSA at SRT. Stish et al. reported that PSAR patients with a PSA < 0.5 µg/L (<500 ng/L) at the start of SRT lived longer without a second relapse than patients with a higher PSA at SRT.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The claim accurately reflects the study’s multivariate analysis findings, correctly using 'associated with' and not implying causation.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Prospective Cohort StudyLevel 2aIn EvidenceWhether achieving undetectable PSA after SRT independently predicts survival across different initiation PSA levels.
Whether achieving undetectable PSA after SRT independently predicts survival across different initiation PSA levels.
What This Would Prove
Whether achieving undetectable PSA after SRT independently predicts survival across different initiation PSA levels.
Ideal Study Design
A prospective cohort of 3,000 men undergoing SRT after prostatectomy, stratified by PSA at SRT initiation (<50, 50–200, >200 ng/L), with serial ultrasensitive PSA measurements post-SRT, recording time to PSA nadir and 10-year survival, adjusting for baseline risk factors.
Limitation: Cannot prove that achieving undetectable PSA causes survival benefit—it may be a marker of less aggressive disease.
Systematic Review & Meta-AnalysisLevel 1aIn EvidenceThe pooled hazard ratio for death associated with post-SRT PSA nadir undetectable vs. detectable.
The pooled hazard ratio for death associated with post-SRT PSA nadir undetectable vs. detectable.
What This Would Prove
The pooled hazard ratio for death associated with post-SRT PSA nadir undetectable vs. detectable.
Ideal Study Design
A meta-analysis of individual patient data from 10+ studies (n≥20,000) comparing survival outcomes in men achieving undetectable vs. detectable PSA nadir after SRT, stratified by pre-SRT PSA level and adjusted for covariates.
Limitation: Definition of 'undetectable' varies across assays and studies.
Randomized Controlled TrialLevel 1bWhether intensifying SRT to achieve undetectable PSA improves survival compared to standard dosing.
Whether intensifying SRT to achieve undetectable PSA improves survival compared to standard dosing.
What This Would Prove
Whether intensifying SRT to achieve undetectable PSA improves survival compared to standard dosing.
Ideal Study Design
A double-blind RCT of 800 men with PSA recurrence, randomized to standard-dose SRT vs. dose-escalated SRT + ADT, with primary endpoint of achieving undetectable PSA nadir at 12 months and secondary endpoint of 7-year overall survival.
Limitation: Does not isolate whether the benefit is due to PSA suppression or tumor control.
Evidence from Studies
Supporting (1)
When prostate cancer comes back after surgery, treating it with radiation while PSA is still super low helps men live longer — and this study shows that the lower the PSA when treatment starts, the better the survival.